This application is directed to medical devices, systems and methods. More specifically, the application is directed to devices, systems and methods for nerve stimulation to treat one or more cardiovascular disorders.
Millions of patients worldwide suffer from cardiovascular diseases, such as hypertension (high blood pressure) and heart failure. Many different pharmaceutical and medical device treatments have been developed to treat hypertension and heart failure, in particular, but many of these treatments have been either completely ineffective or at least ineffective in large subsets of patients. For example, approximately one in ten people with high blood pressure are treatment resistant (in other words, pharmaceuticals do not help to reduce their blood pressure.) Approximately one hundred million people worldwide suffer from treatment resistant high blood pressure. These patients are three times more likely to suffer from a cardiovascular event, such as a heart attack, compared to patients who are able to control their high blood pressure with medications.
A number of different medical devices have been tried to treat drug resistant high blood pressure. One example is a procedure in which a catheter is threaded into the arteries leading to the kidneys, and radiofrequency energy is sent out of the catheter in an attempt to destroy the small nerves surrounding the arteries. Another example is an implantable stimulator for stimulating baroreceptors in the neck by applying energy to the wall of the carotid artery. Unfortunately, these device approaches have not been proven effective. Thus, hundreds of millions of patients suffer from currently-untreatable high blood pressure, which very often leads to serious cardiovascular consequences. Unfortunately, other serious health conditions, such as congestive heart failure and kidney failure, have similar stories.
Therefore, it would be desirable to have improved devices, systems and methods for hypertension, heart failure and/or other cardiovascular conditions. Ideally, such devices, systems and methods would be minimally invasive or less invasive and also effective at treating their target. At least some of these objectives are addressed in this application.
This application describes methods, devices and systems for stimulating nerves to treat hypertension, coronary heart disease, heart failure, kidney disease and/or any of a number of other disease states in humans or animals. Although the following description will focus on the treatment of drug resistant hypertension (high blood pressure), the aspects and principles described below may be used to treat, or adapted for use to treat, any of a number of other cardiovascular or other conditions. Thus, despite the focus of the following description on one disease state, the scope of this application and the methods, devices and systems described herein is not limited to any one disease or condition.
Referring now to
Referring to
The carotid sinus nerve CSN and the vagus nerve X both include afferent nerve fibers, which carry signals to the central nervous system, and efferent nerve fibers, which carry signals away from the central nervous system. In some embodiments, the devices, systems and methods described herein involve stimulating carotid sinus afferent nerve fibers and cardiac-specific vagal afferent nerve fibers, in order to treat hypertension and/or any other suitable condition. In some embodiments, one or both of these types of nerve fibers (carotid sinus afferent nerve fibers and/or cardiac-specific vagal afferent nerve fibers) may be identified before they are stimulated. For the purposes of this application, carotid sinus afferent nerve fibers may be generally referred to as “the carotid sinus nerve,” and cardiac-specific vagal afferent nerve fibers may be generally referred to as “the vagus nerve.” In some embodiments, for example, electrodes of the system described herein may be placed on, over or around the carotid sinus nerve and the vagus nerve, and such an electrode may be used to stimulate carotid sinus afferent nerve fibers and/or cardiac-specific vagal afferent nerve fibers.
Referring now to
The computing device 26 may be any suitable computing device, including but not limited to a smart tablet, smart phone, laptop computer, desktop computer, medical monitoring device or the like. The computing device 26 may transmit data to, and receive data from, the pulse generator 12 wirelessly, using Bluetooth wireless technology or any other wireless protocol. The pulse generator 12 may send data such as but not limited to ECG data sensed by the ECG sensor 24. The computing device 26 may be used to program stimulation parameters into the pulse generator 12 and/or to adjust such parameters. Any suitable information may be shared between the pulse generator 12 and the computing device 26. To ensure patient safety and privacy, a program on the computing device 26 and/or on the pulse generator 12 may include a lock, passkey, firewall and/or any other security measures to restrict access to the pulse generator 12 to only approved healthcare providers or other approved personnel.
Referring now to
In general, the electrode devices 18, 20 of the system 10 are multipolar. In some embodiments, they may be bipolar, but typically they will include more than two electrodes. The number of electrodes may vary, for example, from as few as two to as many as twenty. It may be necessary or advantageous, however, to include as many electrodes as possible, while still keeping the electrode devices 18, 20 relatively small. In some embodiments, such as those described immediately below, the electrode devices 18, 20 may be hexapolar (six electrodes per device).
With reference now to
Referring now to
Next an electrode device is placed 56 over the identified nerves. Then the nerves are stimulated 58, using the electrode. The patient's cardiac cycle may then be sensed 60 (or simply heart rate or other indicator), and the stimulation may then be adjusted 62, based on the sensed cardiac cycle. In one embodiment, for example, the stimulation frequency may be adjusted up or down, depending on the patient's heart rate. In alternative embodiments, any other suitable physiological parameters may be measured and used to adjust one or more stimulation parameters. For example, blood pressure may be measured by any suitable method, such office cuff, finger plethysmography, tonometry, or catheterization, and the measured pressure may then be used to adjust stimulation frequency and/or any other stimulation parameter. The cardiac sensing step 60 and the adjusting step 62 are optional, and in some embodiments one or both of them might not be performed. In some patients, both carotid sinus nerves and vagus nerves (in both sides of the neck) may be treated, in which case the steps of identifying 52, 54 and electrode placement 56 may be repeated for the second side of the neck, before the stimulation step 58. At least some of these steps are described in further detail immediately below.
Unlike the devices and methods used in the study highlighted in
Optimal responses may be defined as peak drop in blood pressure, heart rate, augmentation index, wave reflection coefficient or peak increases in cardiac output, subendocardial viability ratio (SEVR), or any combination thereof, measured for example at follow-up post-implant. In some embodiments, the nerve stimulation system 10 may be used to adjust the frequency of stimulation, such that the number of electrical impulses delivered is constant per cardiac cycle, scaled to the instantaneous heart rate. Calibration of the stimulation may provided by a sensor, such as the ECG sensor 24, a blood pressure waveform, phonocardiography, arterial distension waveform, and/or the like.
In one example of a nerve stimulation method, the implantable portion of the nerve stimulation system 10 may first be implanted in the patient. This portion includes all components of the system 10, other than the computing device 26. The implantable portion of the system 10 may be tested and/or calibrated during implantation. At initial implantation, the system 10 may be turned off or turned on with a given set of stimulation parameters. After implantation, a healthcare provider (physician, physician's assistant, nurse, medical technician, etc.) may meet with the patient and test the stimulation system 10, for example by instructing the pulse generator 12 to stimulate the carotid sinus nerve and vagus nerve for a period of time. In some cases, this may be performed while the patient is engaging in different levels of activity, such as sitting, standing, walking or the like. The healthcare provider may then use the computing device 26 to adjust one or more of the parameters, for example the stimulation frequency, based on the patient's physiological reaction to stimulation and different activity levels. Different patients, for example, may respond differently to different stimulation frequencies, such as but not limited to within the range of 80-120 Hz. The patient may return periodically to the healthcare provider for checkups and adjustments, as needed.
The above description is intended to be a complete description exemplary embodiments and features of a method, device and system for stimulating carotid sinus nerves to treat drug resistant hypertension and/or other conditions. It is meant to be a description of examples only and is not intended to limit the scope of the invention.
This application is a continuation of U.S. application Ser. No. 16/393,536, filed on Apr. 24, 2019, now U.S. Pat. No. 10,918,865, which claims the benefit of U.S. Provisional Patent Application No. 62/662,600, filed Apr. 25, 2018, entitled, “Carotid Sinus Nerve Stimulation.” The disclosure of these priority applications are hereby incorporated by reference in their entirety into the present application.
Number | Name | Date | Kind |
---|---|---|---|
6292703 | Meier et al. | Sep 2001 | B1 |
7509166 | Libbus et al. | Mar 2009 | B2 |
8620422 | Kieval et al. | Dec 2013 | B2 |
9272143 | Libbus | Mar 2016 | B2 |
9763586 | Mokelke et al. | Sep 2017 | B2 |
11819682 | Cates et al. | Nov 2023 | B2 |
20080140141 | Ben-David | Jun 2008 | A1 |
20090275997 | Faltys et al. | Nov 2009 | A1 |
20110046432 | Simon | Feb 2011 | A1 |
20120033080 | Watanabe et al. | Feb 2012 | A1 |
20130131761 | Della Santina et al. | May 2013 | A1 |
20130204328 | Stahmann et al. | Aug 2013 | A1 |
20150202444 | Mandred et al. | Jul 2015 | A1 |
20160250474 | Stack et al. | Sep 2016 | A1 |
20170304630 | Plachta et al. | Oct 2017 | A1 |
20180056074 | Clark et al. | Mar 2018 | A1 |
20180104491 | Lerner | Apr 2018 | A1 |
20180221667 | Libbus et al. | Aug 2018 | A1 |
20200246623 | Libbus et al. | Aug 2020 | A1 |
20210145289 | Thakur et al. | May 2021 | A1 |
20210290957 | Schulhauser et al. | Sep 2021 | A1 |
20220118250 | Libbus et al. | Apr 2022 | A1 |
20220212006 | Rondoni et al. | Jul 2022 | A1 |
20230405329 | Wade et al. | Dec 2023 | A1 |
Number | Date | Country |
---|---|---|
19847446 | Apr 2000 | DE |
WO1997018856 | May 1997 | WO |
WO2015108909 | Jul 2015 | WO |
Entry |
---|
International Search Report and Written Opinion for International Application No. PCT/US2019/028935, mailed Sep. 11, 2019, 14 pages. |
Borst, C. et al., “Optimal frequency of carotid sinus nerve stimulation in treatment of angina pectoris.” Cardiovasc Res. 1974; 8(5); 674-680. |
Examination Report mailed Mar. 20, 2024 in European Patent Application No. 19729887.0, 4 pages. |
International Search Report and Written Opinion mailed Sep. 22, 2023 in International Patent Application No. PCT/US3/68319, 15 pages. |
Number | Date | Country | |
---|---|---|---|
20210205621 A1 | Jul 2021 | US |
Number | Date | Country | |
---|---|---|---|
62662600 | Apr 2018 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16393536 | Apr 2019 | US |
Child | 17156896 | US |